Liraglutide induced an enhanced post-challenge insulin and C-peptide response after the 12-week oral glucose tolerance test and throughout the study period, as well as a reduced post-challenge glycemic excursion, but also increased post-challenge glucagonemia among patients with type 2 diabetes, compared with those who received placebo injection. Researchers noted three features in the response pattern of the liraglutide arm following each OGTT: a lower or similar fasting glucagon compared with placebo, an enhanced post-challenge glucagonemic excursion and a delayed time to peak serum glucagon concentration, occurring at 60 minutes post-challenge, compared with a 30-minute peak in the placebo group. — Kramer CK, et al. J Clin Endocrinol Metab. 2015;doi:10.1210/jc.2015-2725.